½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1574770

¼¼°èÀÇ Áø´Ü¾à ½ÃÀå : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Diagnostic Substances Market by Product Type (Instruments, Kits & Assays, Reagents), Application (Clinical Diagnostics, Forensic, Research), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Áø´Ü¾à ½ÃÀåÀº 2023³â¿¡ 2,048¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 2,156¾ï 3,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.02%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 3,085¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÑ´Ù ±×·¸´Ù°í ¿¹ÃøµË´Ï´Ù.

Áø´Ü¾à ½ÃÀå¿¡´Â ½Ã¾à, Ķ¸®ºê·¹ÀÌÅÍ, Á¦¾î Àç·á, Å°Æ®, °ü·Ã Àåºñ µî Áúº´ Áø´Ü¿¡ »ç¿ëµÇ´Â Àç·á°¡ Æ÷ÇԵ˴ϴÙ. ¸¸¼º Áúȯ ¹× °¨¿°Áõ Áõ°¡·Î Áø´ÜÁ¦´Â ÀÓ»ó ½ÇÇè½Ç, º´¿ø, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç, ¿¬±¸ ±â°ü¿¡¼­ ¸é¹ÐÇÑ Æò°¡, °Ç°­ »óÅ ¸ð´ÏÅ͸µ, È¿°úÀûÀΠȯÀÚ °ü¸®¿¡ »ç¿ëµË´Ï´Ù. ÃÖÁ¾ ÀÌ¿ë »ê¾÷Àº ÇコÄɾî, »ý¸í°øÇÐ, ÀǾàÇ° ¹× ·çƾ °Ë»ç¿¡¼­ °íµµÀÇ ºÐÀÚÁø´Ü¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ¿ëµµ¸¦ °ßÀÎÇÏ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â °Ç°­ ÀÇ½Ä Áõ°¡¿¡ µû¸¥ ¼ö¿ä Áõ°¡, Æ÷ÀÎÆ® ¿Àºê ÄɾîÇü ¹ÙÀÌ¿À ¼¾¼­¿Í °°Àº Çõ½ÅÀûÀÎ Á¦Ç°À» Å°¿ì´Â ±â¼úÀÇ Áøº¸, ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­ÇÏ´Â ±ÔÁ¦ ȯ°æÀÇ Á¤ºñ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Áúº´ÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °Ç°­ °ü¸® ¼º°ú¸¦ °³¼±ÇÏ°í ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´ÜÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 2,048¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 2,156¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 3,085¾ï 3,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 6.02%

À¯Àüü°ú ´Ü¹éÁúüÇÐÀÇ Áøº¸¿¡ ÃßÁøµÈ ¸ÂÃãÇü ÀÇ·áÀÇ µµÀÔ¿¡ »õ·Î¿î ºñÁî´Ï½º ±âȸ°¡ º¸¿©Á® Àü¹®ÀûÀÎ Áø´Ü¾à ¼ö¿ä¸¦ ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á ¹× ½Ç½Ã°£ °Ç°­ ¸ð´ÏÅ͸µ¿¡ Å« ½ÃÀå ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. »õ·Î¿î ±â¼úÀ» ±âÁ¸ ½Ã½ºÅÛ¿¡ ÅëÇÕÇÏ´Â º¹À⼺Àº ¿î¿µ»óÀÇ Àå¾Ö¹°À» ´õ¿í Çâ»ó½ÃÅ°°í ÀÖ½À´Ï´Ù. ȯ°æÀ» ¸ñÇ¥·Î ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó½ÃŲ POC(Point of Care) Áø´Ü Àåºñ °³¹ßÀ» ¸ñÇ¥·Î ÇÏ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Àå¾Ö¹°ÀÌ ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ÀÇ·áºñ Áõ°¡¿Í Áø´Ü ÀýÂ÷ÀÇ ÇÕ¸®È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ÀÇ·á Á¦°ø¾÷ü¿Í ±â¼ú°è ±â¾÷°úÀÇ Çù·Â°ü°è¸¦ °¨¾ÈÇϸé Áø´Ü¾à ½ÃÀåÀº È®´ë¸¦ ÇâÇÏ°í ÀÖ½À´Ï´Ù. ½ÃÀå »óȲÀ» Àß ±Øº¹ÇÏ·Á¸é È®Àå ¼º, Áö¼Ó °¡´É ´É¼º, ȯÀÚ Á᫐ ¼Ö·ç¼Ç¿¡ ÁßÁ¡À» µÐ ÀûÀÀ·Â ÀÖ´Â Á¢±Ù¹ýÀÌ ±ÇÀåµË´Ï´Ù. ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â Áø´Ü¾à ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Áø´ÜÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆľÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Áø´Ü ±â¼úÀÇ Áøº¸¿Í ¸¸¼º ÁúȯÀÇ À¯º´·üÀÇ »ó½ÂÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹Þħ
    • ¼¼°è ÇコÄɾî ÀÎÇÁ¶ó °³¼±À» À§ÇÑ Á¤ºÎ À̴ϼÅƼºê¿Í ÀÚ±Ý Áõ°¡
    • ȯÀÚ Äɾî¿Í °á°ú¸¦ Çâ»ó½ÃÅ°±â À§ÇÑ POC(Point of Care) Áø´Ü ±â±âÀÇ Ã¤¿ë È®´ë
    • Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå È®´ë¸¦ ÃËÁø
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÁøÈ­ÇÏ´Â ÇコÄɾî Á¤Ã¥°ú »óȯÀÇ ¹®Á¦°¡ Áø´Ü¾à ½ÃÀåÀÇ ¼ºÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâ
    • ¹Ì¹ß´Þ Áö¿ª¿¡ À־ÀÇ Áøº¸µÈ Áø´Ü ±â¼ú¿¡ÀÇ ¾×¼¼½º³ª ÀÌ¿ë °¡´É¼ºÀÇ Á¦ÇÑÀÌ ½ÃÀåÀÇ ÀáÀ缺À» ÀúÇØ
  • ½ÃÀå ±âȸ
    • ¾Ï Ä¡·á¿¡ À־ÀÇ ¸ÂÃãÇü ÀǷḦ À§ÇÑ °íµµ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿
    • ¿ø°ÝÁö¿¡¼­ÀÇ ½Å¼ÓÇÑ °¨¿°Áõ °ËÃâÀ» À§ÇÑ POC(Point of Care) Áø´Ü °Ë»ç
    • ½Å°æÅðÇ༺ ÁúȯÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ AI¿¡ ÀÇÇÑ ¿¹Ãø Áø´Ü
  • ½ÃÀåÀÇ °úÁ¦
    • Áø´Ü¾à¿¡ Àͼ÷ÇÑ ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·ÀÌ ½ÃÀåÀÇ ¼ºÀå°ú Çõ½Å¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù

Porter's Five Forces : Áø´Ü¾à ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â Áø´Ü ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡ÇÏ°í Àü·«Àû ±âȸ¸¦ Ž±¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» È°¿ëÇÏ°í, ¾àÁ¡À» ÇØ°áÇÏ°í, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Áø´Ü¾à ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆľÇ

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Áø´Ü ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Áø´Ü¾à ½ÃÀå °æÀï ±¸µµ ÆľÇ

Áø´ÜÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Áø´Ü¾à ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Áø´Ü ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®ÇÏ°í Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆľÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼® ¹× ±ÇÀåÁø´Ü½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Áø´ÜÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ È°¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D È°µ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇÏ°í ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Áø´Ü ±â¼úÀÇ Áøº¸¿Í ¸¸¼º Áúȯ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹Þħ
      • ¼¼°èÀÇ ÇコÄɾî ÀÎÇÁ¶ó °³¼±À» À§ÇÑ Á¤ºÎÀÇ ´ëó¿Í ÀÚ±ÝÀÇ Áõ°­
      • ȯÀÚÀÇ Äɾî¿Í Ä¡·á ¼º°ú¸¦ Çâ»ó½ÃÅ°±â À§ÇØ, POC(Point of Care) Áø´Ü ±â±âÀÇ µµÀÔÀÌ Áõ°¡
      • Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃãÇü ÀÇ·á ¼ö¿ä Áõ°¡°¡ ½ÃÀå È®´ë¸¦ °ßÀÎ
    • ¾ïÁ¦¿äÀÎ
      • ÁøÈ­ÇÏ´Â ÇコÄɾî Á¤Ã¥°ú »óȯ¹®Á¦´Â Áø´Ü¾à ½ÃÀåÀÇ ¼ºÀå¿¡ ¾Ç¿µÇâÀ» ¹ÌĨ´Ï´Ù
      • °³¹ß µµ»ó Áö¿ª¿¡¼­´Â Áøº¸µÈ Áø´Ü ±â¼ú¿¡ ´ëÇÑ Á¢±Ù°ú ÀÌ¿ë °¡´É¼ºÀÌ Á¦ÇÑµÇ¾î ½ÃÀåÀÇ ÀáÀç·ÂÀ» ¹æÇØÇÏ°í ÀÖ½À´Ï´Ù.
    • ±âȸ
      • ¾Ï Ä¡·á¿¡¼­ ¸ÂÃãÇü ÀǷḦ À§ÇÑ °í±Þ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿
      • ¿ø°ÝÁö¿¡¼­ÀÇ °¨¿°ÁõÀÇ ½Å¼ÓÇÑ °ËÃâÀ» À§ÇÑ POC(Point of Care) Áø´Ü °Ë»ç
      • ½Å°æÅðÇ༺ ÁúȯÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ AI ±¸µ¿Çü ¿¹Ãø Áø´Ü
    • °úÁ¦
      • Áø´Ü¾à Àü¹® Áö½ÄÀ» °¡Áø ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·Àº ½ÃÀåÀÇ ¼ºÀå°ú Çõ½Å¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Áø´Ü¾à ½ÃÀå : Á¦Ç° À¯Çüº°

  • ±â±â
    • ºÐ¼®±â
    • Â÷¼¼´ë ½ÃÄö½Ì
    • PCR ±â°è
  • Å°Æ® ¹× ºÐ¼®
    • ¿¤¸®»çŶ
    • ·¡ÅÍ·² ÇÃ·Î¿ì ºÐ¼®
    • PCR Å°Æ®
  • ½Ã¾à
    • Ç×ü
    • ÆéƼµå
    • ´Ü¹éÁú

Á¦7Àå Áø´Ü¾à ½ÃÀå : ¿ëµµº°

  • ÀÓ»ó Áø´Ü
    • ½ÉÀ庴ÇÐ
    • °¨¿°Áõ
    • Á¾¾çÇÐ
  • ¹ýÀÇÇÐ
    • º´¸®ÇÐ
    • µ¶¹°ÇÐ
  • ¿¬±¸
    • â¾à
    • À¯ÀüüÇÐ
    • ´Ü¹éÁúüÇÐ

Á¦8Àå Áø´Ü¾à ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Áø´Ü ½ÇÇè½Ç
    • º´¿ø ±â¹ÝÀÇ ½ÇÇè½Ç
    • µ¶¸³°è ½ÇÇè½Ç
  • º´¿ø ¹× Ŭ¸®´Ð
    • »ç¸³º´¿ø
    • °ø¸³º´¿ø
  • Á¦¾àȸ»ç
    • ÀÓ»ó½ÃÇè
    • ÀǾàÇ° °³¹ß
  • ¿¬±¸±â°ü
    • Çмú¿¬±¸
    • Á¤ºÎÁ¶»ç

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Áø´Ü¾à ½ÃÀå

  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Áø´Ü¾à ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Áø´Ü¾à ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍÅ°
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Cepheid
  • 7. Danaher Corporation
  • 8. DiaSorin SpA
  • 9. Genomic Health Inc.
  • 10. Hoffmann-La Roche AG
  • 11. Hologic Inc.
  • 12. Illumina Inc.
  • 13. Merck KGaA
  • 14. Ortho Clinical Diagnostics
  • 15. PerkinElmer Inc.
  • 16. Qiagen NV
  • 17. Quidel Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation
  • 20. Thermo Fisher Scientific Inc.
BJH 24.11.07

The Diagnostic Substances Market was valued at USD 204.84 billion in 2023, expected to reach USD 215.63 billion in 2024, and is projected to grow at a CAGR of 6.02%, to USD 308.53 billion by 2030.

The diagnostic substances market encompasses materials used for diagnosing diseases, encompassing reagents, calibrators, control materials, kits, and related instruments. Necessitated by the increasing prevalence of chronic and infectious diseases, diagnostic substances are applied in clinical laboratories, hospitals, point-of-care testing, and research institutions for conducting meticulous assessments, monitoring health conditions, and ensuring effective patient management. End-use industries span healthcare, biotechnology, and pharmaceuticals, driving diverse applications from routine tests to advanced molecular diagnostics. Key growth influencers include escalating demand due to rising health awareness, technological advancements fostering innovative products like point-of-care biosensors, and supportive regulatory environments accelerating market entry. Additionally, the growing incidence of diseases necessitates accurate, swift diagnosis to improve healthcare outcomes and reduce costs.

KEY MARKET STATISTICS
Base Year [2023] USD 204.84 billion
Estimated Year [2024] USD 215.63 billion
Forecast Year [2030] USD 308.53 billion
CAGR (%) 6.02%

Emerging opportunities are notably visible in the adoption of personalized medicine, fueled by genomic and proteomic advancements, propelling demand for specialized diagnostic substances. Leveraging artificial intelligence and big data analytics in diagnostics offers substantial market potential for precision medicine and real-time health monitoring. However, challenges such as high development costs, stringent regulatory landscapes, and data privacy issues can impede market progression. Complexities in integrating new technologies within existing systems further pose operational hurdles. Encouragement of innovation and research is directed towards developing point-of-care diagnostic devices with enhanced sensitivity and specificity, targeting resource-constrained settings to cater to unmet needs in developing regions. Exploring biomarker discovery and validation, alongside lab-on-a-chip technologies, presents promising avenues for growth.

Despite these hurdles, the diagnostic substances market is poised for expansion, given the increasing healthcare expenditures, alongside collaborations between healthcare providers and technological firms striving to streamline diagnostic procedures. An adaptable approach emphasizing scalability, sustainability, and patient-centric solutions is recommended to navigate the evolving market landscape successfully. Subsequently, embracing eco-friendly production processes and digital health innovations ensures sustained competitive advantage for industry participants.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diagnostic Substances Market

The Diagnostic Substances Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Advancements in diagnostic technologies and rising prevalence of chronic diseases boosting market growth
    • Increasing government initiatives and funding to improve healthcare infrastructure worldwide
    • Growing adoption of point-of-care diagnostic devices to enhance patient care and outcomes
    • Rising demand for early disease detection and personalized medicine driving market expansion
  • Market Restraints
    • Evolving healthcare policies and reimbursement issues negatively impact diagnostic substances market growth
    • Limited accessibility and availability of advanced diagnostic technologies in underdeveloped regions hinder market potential
  • Market Opportunities
    • Advanced diagnostic biomarkers for personalized medicine in cancer treatment
    • Point-of-care diagnostic tests for rapid infectious disease detection in remote areas
    • AI-driven predictive diagnostics for early detection of neurodegenerative diseases
  • Market Challenges
    • Limited availability of skilled professionals with expertise in diagnostic substances impacts market growth and innovation

Porter's Five Forces: A Strategic Tool for Navigating the Diagnostic Substances Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diagnostic Substances Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diagnostic Substances Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diagnostic Substances Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diagnostic Substances Market

A detailed market share analysis in the Diagnostic Substances Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diagnostic Substances Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diagnostic Substances Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diagnostic Substances Market

A strategic analysis of the Diagnostic Substances Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diagnostic Substances Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, Cepheid, Danaher Corporation, DiaSorin S.p.A., Genomic Health Inc., Hoffmann-La Roche AG, Hologic Inc., Illumina Inc., Merck KGaA, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen N.V., Quidel Corporation, Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Diagnostic Substances Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments, Kits & Assays, and Reagents. The Instruments is further studied across Analyzers, Next-Generation Sequencing, and PCR Machines. The Kits & Assays is further studied across Elisa Kits, Lateral Flow Assays, and PCR Kits. The Reagents is further studied across Antibodies, Peptides, and Proteins.
  • Based on Application, market is studied across Clinical Diagnostics, Forensic, and Research. The Clinical Diagnostics is further studied across Cardiology, Infectious Diseases, and Oncology. The Forensic is further studied across Pathology and Toxicology. The Research is further studied across Drug Discovery, Genomics, and Proteomics.
  • Based on End User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, Pharmaceutical Companies, and Research Institutes. The Diagnostic Laboratories is further studied across Hospital-Based Labs and Independent Labs. The Hospitals & Clinics is further studied across Private Hospitals and Public Hospitals. The Pharmaceutical Companies is further studied across Clinical Trials and Drug Development. The Research Institutes is further studied across Academic Research and Government Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Advancements in diagnostic technologies and rising prevalence of chronic diseases boosting market growth
      • 5.1.1.2. Increasing government initiatives and funding to improve healthcare infrastructure worldwide
      • 5.1.1.3. Growing adoption of point-of-care diagnostic devices to enhance patient care and outcomes
      • 5.1.1.4. Rising demand for early disease detection and personalized medicine driving market expansion
    • 5.1.2. Restraints
      • 5.1.2.1. Evolving healthcare policies and reimbursement issues negatively impact diagnostic substances market growth
      • 5.1.2.2. Limited accessibility and availability of advanced diagnostic technologies in underdeveloped regions hinder market potential
    • 5.1.3. Opportunities
      • 5.1.3.1. Advanced diagnostic biomarkers for personalized medicine in cancer treatment
      • 5.1.3.2. Point-of-care diagnostic tests for rapid infectious disease detection in remote areas
      • 5.1.3.3. AI-driven predictive diagnostics for early detection of neurodegenerative diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled professionals with expertise in diagnostic substances impacts market growth and innovation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diagnostic Substances Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
    • 6.2.1. Analyzers
    • 6.2.2. Next-Generation Sequencing
    • 6.2.3. PCR Machines
  • 6.3. Kits & Assays
    • 6.3.1. Elisa Kits
    • 6.3.2. Lateral Flow Assays
    • 6.3.3. PCR Kits
  • 6.4. Reagents
    • 6.4.1. Antibodies
    • 6.4.2. Peptides
    • 6.4.3. Proteins

7. Diagnostic Substances Market, by Application

  • 7.1. Introduction
  • 7.2. Clinical Diagnostics
    • 7.2.1. Cardiology
    • 7.2.2. Infectious Diseases
    • 7.2.3. Oncology
  • 7.3. Forensic
    • 7.3.1. Pathology
    • 7.3.2. Toxicology
  • 7.4. Research
    • 7.4.1. Drug Discovery
    • 7.4.2. Genomics
    • 7.4.3. Proteomics

8. Diagnostic Substances Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
    • 8.2.1. Hospital-Based Labs
    • 8.2.2. Independent Labs
  • 8.3. Hospitals & Clinics
    • 8.3.1. Private Hospitals
    • 8.3.2. Public Hospitals
  • 8.4. Pharmaceutical Companies
    • 8.4.1. Clinical Trials
    • 8.4.2. Drug Development
  • 8.5. Research Institutes
    • 8.5.1. Academic Research
    • 8.5.2. Government Research

9. Americas Diagnostic Substances Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diagnostic Substances Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diagnostic Substances Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Cepheid
  • 7. Danaher Corporation
  • 8. DiaSorin S.p.A.
  • 9. Genomic Health Inc.
  • 10. Hoffmann-La Roche AG
  • 11. Hologic Inc.
  • 12. Illumina Inc.
  • 13. Merck KGaA
  • 14. Ortho Clinical Diagnostics
  • 15. PerkinElmer Inc.
  • 16. Qiagen N.V.
  • 17. Quidel Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation
  • 20. Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦